AH AHCL
Anlon Healthcare Q2 2027
AHAHCL

Anlon Healthcare Q2 FY27 results (Jul–Sep 2026) and concall

Healthcare · Concall AI · Call held 3 Nov 2026

Management summary

  • Anlon Healthcare demonstrated strong operational growth in Q2 FY27, with consolidated revenue doubling YoY to ₹105.61 crores and H1 FY27 performance exceeding the full-year FY26 topline.
  • EBITDA margins rebounded sharply to 23.9% from 17.8% in Q1 FY27, driven by successful price revisions to absorb elevated raw material costs.
  • The company is actively executing a ₹130 crore greenfield expansion at Rajkot to add 1,200 MTPA capacity by Q1 FY28.
  • Expanding into finished dosages, biologics, and medical devices..

Source: Inve concall analysis and management guidance record.

Highlights

  • Revenue from operations grew 102.3% YoY to ₹105.61 crores in Q2 FY27 and 125.9% YoY to ₹193.17 crores in H1 FY27

  • EBITDA margin expanded sequentially by over 600 bps from 17.8% in Q1 FY27 to 23.9% in Q2 FY27

  • PAT grew 84.4% YoY to ₹17.18 crores in Q2 FY27 and 97.9% YoY to ₹25.46 crores in H1 FY27

  • Operating cash flow improved substantially with net cash used standing at ₹7.94 crores in H1 FY27 compared to ₹79.44 crores in FY26

What they filed

Q2 FY27: revenue up 96.2%, net profit up 88.9% against the same quarter last year.

₹ Cr · quarterly
Line itemQ3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27Q2 FY27
Revenue9 49 33 52 36 +285%4 −92%163 +394%102 +96%
EBITDA1 17 6 14 12 +1969%15 −12%16 +167%25 +79%
Net profit-2 17 4 9 5 +301%11 −35%8 +100%17 +89%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Guidance & targets

Revenue

  • FY27 Consolidated Revenue Revenue · FY27 · High confidence INR 380 - 400 crores

    From INR 380 - 400 crores today

  • FY28 Consolidated Revenue Revenue · FY28 · High confidence INR 650 - 700 crores

Source: Inve Guidance Tracker — management targets and direct quotes from the earnings call transcript.

Q&A highlights

1 direct
Auditor review coverage across consolidated subsidiaries Partial
No, I think consolidated is also reviewed by the auditor... I think the result what we have published in that both are given separately stand-alone and consolidated both.

Analyst questioned compliance with SEBI's 80% audited revenue coverage requirement on consolidated results, highlighting subsidiary audit transparency.

Asked by Prateek Srivastava, Nivesh Vista

CDMO commercial supply delays and revenue recognition Direct
We have not started yet because see the commercial quantity and the details we already received from the customer, I think it is still delayed by 1 or 2 months. So mostly by end of last month of Q3 or maybe first month of Q4, we can be able to supply the first commercial segment.

Confirms a 1-2 month execution delay for the first CDMO molecule, while molecules 2 and 3 are pushed to H1 FY28.

Asked by Vaibhav Mishra, Finvestors Research

Unlock risks & concerns, Q3 FY27 watchlist, and full call analysis

You’re reading a preview. Opening the full call uses 1 concall credit and unlocks:

  • 6 risks, concerns & management red flags
  • 4 watchlist triggers for Q3 FY27
  • +6 more guidance targets & verbatim management quotes
  • +6 more analyst Q&A exchanges & evasion checks
  • Capital allocation & full section-by-section narrative

Sign in to use your monthly call allowance.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared and our regulatory disclaimer. · Share on WhatsApp · Scorecard image